We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+14.16%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$8.05M
Cap. Flow
-$5.69M
Cap. Flow %
-2.06%
Top 10 Hldgs %
77.48%
Holding
98
New
6
Increased
9
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$25.7M
2
COLL icon
Collegium Pharmaceutical
COLL
+$1.09M
3
PFE icon
Pfizer
PFE
+$814K
4
MDT icon
Medtronic
MDT
+$693K
5
HELP
Cybin Inc
HELP
+$614K

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$14.2M
2
CLOZ icon
Panagram BBB-B CLO ETF
CLOZ
+$13.3M
3
GSK icon
GSK
GSK
+$2.66M
4
DMRC icon
Digimarc Corp
DMRC
+$2.25M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.89M

Sector Composition

Rank Sector Weight
1 Materials 29.62%
2 Healthcare 26.2%
3 Financials 16.91%
4 Communication Services 7.75%
5 Industrials 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RHP icon
26
Ryman Hospitality Properties
RHP
$7.99B
$1.25M 0.45%
12,000
– –
MREO
27
Mereo BioPharma
MREO
$49.5M
$1.16M 0.42%
331,000
– –
ATYR
28
aTyr Pharma
ATYR
$50M
$1.12M 0.4%
308,133
+200,959
+188% +$608K
COLL icon
29
Collegium Pharmaceutical
COLL
$1.17B
$943K 0.34%
+32,927
New +$1.09M
XBI icon
30
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$901K 0.33%
10,000
– –
ABBV icon
31
AbbVie
ABBV
$450B
$895K 0.32%
5,037
– –
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.6B
$818K 0.3%
20,866
– –
VRTX icon
33
Vertex Pharmaceuticals
VRTX
$123B
$805K 0.29%
2,000
– –
KMB icon
34
Kimberly-Clark
KMB
$36B
$786K 0.28%
6,000
– –
DD icon
35
DuPont de Nemours
DD
$18.3B
$757K 0.27%
7,911
– –
MSFT icon
36
Microsoft
MSFT
$2.93T
$674K 0.24%
1,600
– –
CTVA icon
37
Corteva
CTVA
$58.4B
$659K 0.24%
11,563
– –
MDT icon
38
Medtronic
MDT
$106B
$639K 0.23%
+8,000
New +$693K
EOLS icon
39
Evolus
EOLS
$377M
$636K 0.23%
57,570
– –
AAPL icon
40
Apple
AAPL
$4.9T
$625K 0.23%
2,494
– –
MGTX icon
41
MeiraGTx Holdings
MGTX
$1.15B
$579K 0.21%
95,080
+90,377
+1,922% +$530K
MDLZ icon
42
Mondelez International
MDLZ
$78.3B
$538K 0.19%
9,000
– –
HELP
43
Cybin Inc
HELP
$449M
$533K 0.19%
+60,446
New +$614K
CNQ icon
44
Canadian Natural Resources
CNQ
$91.5B
$519K 0.19%
16,800
– –
XOMA
45
DELISTED
Xoma
XOMA
$518K 0.19%
19,722
– –
VRDN icon
46
Viridian Therapeutics
VRDN
$1.99B
$479K 0.17%
+25,000
New +$544K
IBM icon
47
IBM
IBM
$200B
$471K 0.17%
2,142
– –
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$11.5B
$381K 0.14%
5,800
-28,200
-83% -$1.89M
LLY icon
49
Eli Lilly
LLY
$1.05T
$232K 0.08%
300
– –
NVDA icon
50
NVIDIA
NVDA
$4.91T
$172K 0.06%
1,280
– –
1
2
3 4

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
TT
TI-Trust Quincy, Illinois $168M AUM 24.32% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return

David M. Knott Jr's Q4 2024 Portfolio in Review

As of Q4 2024, David M. Knott Jr held 98 positions worth $277M, down 2.8% from $285M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

David M. Knott Jr's Q4 2024 filing shows 6 new, 9 increased, 11 reduced and 9 closed positions. Its largest new stake was Collegium Pharmaceutical: 32,927 shares worth $943K. The largest sale was Calumet Specialty Products, an estimated $14.2M.

By sector, the portfolio is most concentrated in Materials at 30% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.

  • David M. Knott Jr's largest Q4 2024 buy was Collegium Pharmaceutical: 32,927 shares worth $943K.
  • David M. Knott Jr added most to Janus Henderson AAA CLO ETF in Q4 2024, an estimated $25.7M increase.
  • David M. Knott Jr's biggest Q4 2024 reduction was Calumet Specialty Products, cutting an estimated $14.2M.
  • David M. Knott Jr fully exited GSK in Q4 2024, selling an estimated $2.66M.
  • David M. Knott Jr's ten largest holdings make up 77% of its $277M portfolio in Q4 2024.
  • David M. Knott Jr opened 6 new positions and closed 9 in Q4 2024.
  • David M. Knott Jr's portfolio value fell 2.8% quarter-over-quarter to $277M.

Based on David M. Knott Jr's 13F filing for Q4 2024, filed 12 Feb 2025.